Month: May 2020

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal 2020 second quarter.“We are pleased to report that we are approaching the conclusion of the double-blind Phase 2 Parkinson’s disease dementia trial with ANAVEX®2-73 (blarcamesine) and we expect to report top line results by mid-2020,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “Both the Alzheimer’s disease Phase 2b/3 trial and clinical Rett syndrome programs are also...

AMRYT PHARMA PLC(“Amryt” or the “Company”)FILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101Amryt, a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces that the global brand name for its lead development product AP101 will be FILSUVEZ®.Amryt announced on 23 April 2020 that the Company has completed recruitment into its Global Phase 3 clinical study (“EASE”) in Epidermolysis Bullosa (“EB”) and anticipates top line data read out in late Q3 / early Q4 2020.Establishing the brand name for AP101 is another important step forward in ensuring readiness for the global launch of FILSUVEZ®.About EBEB is a rare and distressing genetic skin disorder affecting young children and adults for which...

Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension study of sepofarsen, including data from contralateral eye treatment, on track to be reported in H2 2020;Three clinical stage RNA therapies in development for inherited retinal diseases, with fourth ophthalmic program slated to enter mechanistic proof-of-concept studies;ProQR anticipates its cash runway will fund operations into H2 2022LEIDEN, Netherlands & CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) —  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases,...

RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%.Consolidated revenues € 429.2 million, +12.1%.EBITDA (1) € 172.9 million, +20.1%Operating income € 148.4 million, +17.8%.Net income € € 111.2 million, + 20.7%Adjusted net income (2) € 125.2 million, +23.5%.Net financial position (3):  net debt of € 880.8 million; € 902.7 million at 31 December 2019.Shareholders’ equity € 1,242.9 million.Isturisa® (osilodrostat) approved in Europe and in the U.S.A., filed for approval in Japan.. Milan, 7 May 2020 – The Board of Directors of Recordati S.p.A. approved the Group’s consolidated results for the first quarter of 2020 prepared in accordance with the recognition and measurement criteria prescribed by the International Financial Reporting Standards (IFRS). These financial statements will be available today at the...

RECORDATI: RISULTATI ECONOMICI IN CRESCITA NEL PRIMO TRIMESTRE DEL 2020. RICAVI +12,1%, EBITDA +20,1%.Ricavi netti consolidati € 429,2 milioni, +12,1%.EBITDA (1) € 172,9 milioni, +20,1%.Utile operativo € 148,4 milioni, +17,8%.Utile netto € 111,2 milioni, + 20,7%.Utile netto rettificato (2) € 125,2 milioni, +23,5%.Posizione finanziaria netta (3): debito netto di € 880,8 milioni; € 902,7 milioni al 31 dicembre 2019.Patrimonio netto € 1.242,9 milioni.Isturisa® (osilodrostat) approvata commercializzazione in Europa e negli Stati Uniti d’America, designazione farmaco orfano confermata. Richiesta autorizzazione presentata in Giappone.Milano, 7 maggio 2020 – Il Consiglio di Amministrazione della Recordati S.p.A. ha approvato, quale rendicontazione finanziaria aggiuntiva su base volontaria (4), la relazione finanziaria al 31 marzo 2020. La relazione...

New high-volume production test allows Biomerica to expand international distribution to better meet demand of its 10-minute test for coronavirus exposure. The test can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor’s office utilizing blood from a finger prick. Biomerica also announced it is now filling and has shipped commercial orders of its previously announced version of the product to Company distributors who are supplying customers that include NATO, and government agencies in Germany, Switzerland and the Netherlands. The suggested price point of the new high-volume test maintains at $10 per patient price.IRVINE, Calif., May 07, 2020 (GLOBE NEWSWIRE) — Biomerica Inc. (NASDAQ: BMRA) today announced it has received a CE mark and launched a new high-volume production version of its COVID-19...

ATLANTA, May 07, 2020 (GLOBE NEWSWIRE) — The Providence Service Corporation (the “Company” or “Providence”) (Nasdaq: PRSC), the nation’s largest provider of non-emergency medical transportation (“NEMT”) programs and holder of a minority interest in Matrix Medical Network, today reported financial results for the three months ended March 31, 2020.First Quarter 2020 Highlights:Revenue from continuing operations of $367.3 millionIncome from continuing operations, net of tax, of $16.3 million, and earnings of $1.02 per diluted common shareAdjusted EBITDA of $16.0 million, Adjusted Net Income of $9.9 million and Adjusted EPS of $0.58Net cash provided by operating activities of $38.8 millionAt March 31, 2020, cash, net of debt, of $92.4 million, compared to $61.4 million at December 31, 2019Subsequent Event:On May 6, 2020, Providence’s...

Significantly Improved Cash Position and Balance SheetClosed Aevi Merger; Transformed into Orphan and Rare Disease BiotechROCKVILLE, Md., May 07, 2020 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced first quarter results for 2020. The Company significantly improved its balance sheet as a result of an appreciation in an investment and as a result of an income tax receivable from the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act which are expected to generate cash proceeds of $15 million in the second quarter ($12.8 million of which has already been realized). “I am extremely proud of the team as we have merged seamlessly across the business.  We are poised...

BANNOCKBURN, Ill., May 07, 2020 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the first quarter ended March 31, 2020.Given the merger between HC Group Holdings II, Inc. (“Option Care”) and BioScrip, Inc. (“BioScrip”) to form Option Care Health on August 6, 2019, comparisons to historical periods are relative to legacy Option Care only and incorporate BioScrip results from August 6, 2019 prospectively. Further, as reported on February 3, 2020, the Company recently completed a reverse 1-for-4 stock split and, as a result, all per share data below is reported incorporating the effect of the reverse stock split as if it was effective for all periods reported.First...